|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Epidemiology/Health Services/Psychosocial Research |
Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S.
From the Caro Research Institute, Concord, Massachusetts.
OBJECTIVE—To model the lifetime costs associated with complications of type 2 diabetes.
RESEARCH DESIGN AND METHODS—A cohort of 10,000 patients with diabetes was simulated using a model based on existing epidemiological studies. Complication rates were estimated for various stages of macrovascular disease, nephropathy, retinopathy, neuropathy, and hypoglycemia. At the beginning of the simulation, patients were assumed to have been treated for 5 years and have a mean HbA1c of 8.4. From the U.K. Prospective Diabetes Study, it was estimated that on current therapies, the HbA1c would drift upward on average 0.15% per year. Direct medical costs of managing each complication were estimated (in 2000 U.S. dollars) from all-payor databases, surveys, and literature.
RESULTS—Macrovascular disease was estimated to be the largest cost component, accounting for 85% of cumulative costs of complications over the first 5 years. The costs of complications were estimated to be $47,240 per patient over 30 years, on average. The management of macrovascular disease is estimated to be the largest cost component, accounting for 52% of the costs; nephropathy accounts for 21%, neuropathy accounts for 17%, and retinopathy accounts for 10% of the costs of complications.
CONCLUSIONS—The complications of diabetes account for substantial costs, with management of macrovascular disease being the largest and earliest. If improving glycemic control prevents complications, it will reduce these costs.
Abbreviations: ADA, American Diabetes Association • ESRD, end-stage renal disease • UKPDS, U.K. Prospective Diabetes Study.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  N. C. Martinez and J. Bader Analysis of Behavioral Risk Factor Surveillance System Data to Assess the Health of Hispanic Americans With Diabetes in El Paso County, Texas The Diabetes Educator, July 1, 2007; 33(4): 691 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Bullano, M. D. Fisher, W. D. Grochulski, L. Menditto, and V. J. Willey Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2473 - 2482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Johnson, S. L. Pohar, and S. R. Majumdar Health Care Use and Costs in the Decade After Identification of Type 1 and Type 2 Diabetes: A population-based study. Diabetes Care, November 1, 2006; 29(11): 2403 - 2408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Chaudhry, J. C. Stevens, J. Kincaid, and Y. T. So Practice Advisory: Utility of surgical decompression for treatment of diabetic neuropathy: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, June 27, 2006; 66(12): 1805 - 1808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bottomley, A. J Palmer, R. Williams, J. Dormandy, and M. Massi-Benedetti Review: PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events -- economic implications? The British Journal of Diabetes & Vascular Disease, March 1, 2006; 6(2): 63 - 70. [Abstract] [PDF]
|
|
|
|
 |
|
 D. L. Leslie and R. A. Rosenheck Pharmacotherapy and Health Care Costs Among Patients With Schizophrenia and Newly Diagnosed Diabetes Psychiatr Serv, July 1, 2005; 56(7): 803 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Oliva, F. Lobo, B. Molina, and S. Monereo Direct Health Care Costs of Diabetic Patients in Spain Diabetes Care, November 1, 2004; 27(11): 2616 - 2621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Consensus Panel Guidelines for Computer Modeling of Diabetes and Its Complications Diabetes Care, September 1, 2004; 27(9): 2262 - 2265. [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Hoerger, R. Harris, K. A. Hicks, K. Donahue, S. Sorensen, and M. Engelgau Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis Ann Intern Med, May 4, 2004; 140(9): 689 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-S. Kwon, J.-H. Cho, H.-S. Kim, B.-R. Song, S.-H. Ko, J.-M. Lee, S.-R. Kim, S.-A. Chang, H.-S. Kim, B.-Y. Cha, et al. Establishment of Blood Glucose Monitoring System Using the Internet Diabetes Care, February 1, 2004; 27(2): 478 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Polydefkis, J. W. Griffin, and J. McArthur New Insights Into Diabetic Polyneuropathy JAMA, September 10, 2003; 290(10): 1371 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Brandle, H. Zhou, B. R.K. Smith, D. Marriott, R. Burke, B. P. Tabaei, M. B. Brown, and W. H. Herman The Direct Medical Cost of Type 2 Diabetes Diabetes Care, August 1, 2003; 26(8): 2300 - 2304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A Reasner and B. Goke Overcoming the barriers to effective glycaemic control for type 2 diabetes The British Journal of Diabetes & Vascular Disease, July 1, 2002; 2(4): 290 - 295. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |